BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

  April 23, 2026

   · 

  4 min read
• Press Releases

  Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications

  April 23, 2026

   · 

  3 min read
• Press Releases

  Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

  April 23, 2026

   · 

  6 min read
• Press Releases

  MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

  April 23, 2026

   · 

  3 min read
• Press Releases

  Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

  April 23, 2026

   · 

  1 min read
• Press Releases

  Collegium to Report First Quarter 2026 Financial Results on May 7, 2026

  April 23, 2026

   · 

  1 min read
• Press Releases

  Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

  April 23, 2026

   · 

  9 min read
• Press Releases

  Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

  April 23, 2026

   · 

  7 min read
• Press Releases

  CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

  April 23, 2026

   · 

  4 min read
• Press Releases

  Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors

  April 23, 2026

   · 

  4 min read